|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||31.58 - 31.58|
|52 Week Range||26.26 - 31.91|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.70%|
The FDA's approval of Regeneron Pharmaceuticals' Kevzara was based on the pivotal Phase 3 MOBILITY and TARGET clinical trials.
Three reasons to dive into blue-chip ETFs right now.
ETFs can be a good choice for tax-sensitive investors, but remember they aren't tax-exempt.